Novel bispecific broad spectrum nanobody
Active Awarded Last action
- Contract number
- HT942526FE010
- Awardee
-
Eitr Biologics, Inc. UEI HX49LZLY32G5
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $926,999
Award facts
- Contract value 100% obligated
- $926,999.13 Current and potential, with all options
- Completion date 39% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency has awarded a $927K firm fixed-price delivery order to Eitr Biologics, Inc., a San Diego-based biotechnology company specializing in antibody-based therapeutics and nanotherapeutics. The contract, awarded February 1, 2026, with an ultimate completion date of December 31, 2027, focuses on the development of novel bispecific broad-spectrum nanobodies intended to address biological threats. Performance will take place in San Diego, California. This delivery order carries no small business set-aside designation and represents a continuation of the Defense Health Agency's partnership with Eitr Biologics on medical countermeasure development.
This award is issued under Eitr Biologics' single-award Indefinite Delivery Vehicle with the Defense Health Agency, valued at $4.39M through August 2028, which is specifically structured for developing novel nanotherapeutics to combat biological threats such as pneumonic plague. The company has established a track record with the Defense Health Agency through prior task orders and delivery orders focused on nanotherapeutic research targeting pathogens including Yersinia pestis, and has also secured federal research funding from the National Institute of Allergy and Infectious Diseases for Phase I Small Business Innovation Research grants on bispecific nanotherapeutics as broad-spectrum antivirals and betacoronavirus medical countermeasures.
Quick answers
Who was awarded contract HT942526FE010?
HT942526FE010 was awarded to Eitr Biologics, Inc. by Defense Health Agency (Department of Defense) on February 1, 2026.
How much is contract HT942526FE010 worth?
The government has obligated $926,999 on HT942526FE010.
Is contract HT942526FE010 an order under another contract?
Yes. HT942526FE010 is a delivery order under HT942523D0011, an indefinite delivery contract.
Was contract HT942526FE010 competed?
The extent of competition for HT942526FE010 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award